Does CEMIPLIMAB-RWLC Cause Malignant neoplasm progression? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Malignant neoplasm progression have been filed in association with CEMIPLIMAB-RWLC. This represents 0.7% of all adverse event reports for CEMIPLIMAB-RWLC.
11
Reports of Malignant neoplasm progression with CEMIPLIMAB-RWLC
0.7%
of all CEMIPLIMAB-RWLC reports
5
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CEMIPLIMAB-RWLC?
Of the 11 reports, 5 (45.5%) resulted in death, 3 (27.3%) required hospitalization, and 1 (9.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CEMIPLIMAB-RWLC. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does CEMIPLIMAB-RWLC Cause?
Death (128)
Disease progression (101)
Fatigue (71)
Off label use (68)
Rash (64)
Dyspnoea (55)
Pyrexia (52)
Pruritus (44)
Asthenia (42)
Diarrhoea (42)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CEMIPLIMAB-RWLC Alternatives Have Lower Malignant neoplasm progression Risk?
CEMIPLIMAB-RWLC vs CENEGERMIN-BKBJ
CEMIPLIMAB-RWLC vs CENOBAMATE
CEMIPLIMAB-RWLC vs CEPHALEXIN
CEMIPLIMAB-RWLC vs CERITINIB
CEMIPLIMAB-RWLC vs CERLIPONASE ALFA